EFFICACY AND SYSTEMIC EFFECT OF THE COMBINATION OF FLUTICASONE FUROATE AND VILANTEROL IN THE TREATMENT OF ASTHMA

Abstract

Fluticasone furoate/vilanterol (FF/VI) is a fixed-dose combination of inhaled glucocorticoid (ICS) and longacting beta-2 agonist (LABA) approved for the treatment of asthma in adults and adolescents aged 12 years and older. This combination reduces asthma symptoms and exacerbation rates (including severe asthma-related exacerbations). Clinical research has demonstrated that FF/VI significantly improves respiratory function by measuring the change of the forced expiratory volume in 1 second compare to ICS monotherapy and other ICS/LABA alternatives. Moreover, there is evidence that FF can provide greater protection against airway hyperresponsiveness, with less systemic activity than other ICSs, which might cause less systemic adverse events in patients with asthma. These findings suggest that FF/VI is a useful alternative for patients with moderate-to-severe asthma.